Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 3:31 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 313–336 of 2,386 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Progressive Clear all
Completed Phase 3 Interventional Results available

A Study of Trastuzumab Emtansine in Comparison With Treatment of Physician's Choice in Participants With HER2-positive Breast Cancer Who Have Received at Least Two Prior Regimens of HER2-directed Therapy

NCT01419197
View directory record Official record
Conditions
Breast Cancer
Interventions
Trastuzumab emtansine, Treatment of physician's choice
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
602 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
59
States / cities
Tucson, Arizona • Hot Springs, Arkansas • Hayward, California + 52 more
Source: ClinicalTrials.gov public record
Updated Oct 12, 2016 · Synced Oct 23, 2026, 3:31 PM EDT
Completed Phase 2 Interventional Results available

Erlotinib and Sorafenib in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme

NCT00445588
View directory record Official record
Conditions
Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Recurrent Adult Brain Tumor
Interventions
erlotinib hydrochloride, sorafenib tosylate, pharmacological study
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
9
States / cities
Birmingham, Alabama • Tampa, Florida • Atlanta, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2016 · Synced Oct 23, 2026, 3:31 PM EDT
Completed Phase 2 Interventional

A Research Study for Patients With Metastatic Renal Cell Carcinoma

NCT00106613
View directory record Official record
Conditions
Carcinoma, Renal Cell, Neoplasm Metastasis
Interventions
FK228 (romidepsin)
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
3
States / cities
Duarte, California • Chicago, Illinois • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 18, 2019 · Synced Oct 23, 2026, 3:31 PM EDT
Completed Not applicable Interventional Results available

Impact of a Mobility Program

NCT02674503
View directory record Official record
Conditions
Hospitalization
Interventions
Walking, Friendly visit
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
50 Years and older
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
2
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jul 5, 2024 · Synced Oct 23, 2026, 3:31 PM EDT
Terminated Phase 2 Interventional Results available

Trial of Adalimumab in Progressive Sarcoidosis

NCT00311246
View directory record Official record
Conditions
Sarcoidosis
Interventions
Adalimumab
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 85 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 25, 2020 · Synced Oct 23, 2026, 3:31 PM EDT
Completed Not applicable Interventional

Deep Clinical Trajectory Modeling to Optimize Accrual to Cancer Clinical Trials

NCT06888089
View directory record Official record
Conditions
Cancer
Interventions
AI-assisted MatchMiner Platform
Other
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
20,707 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 21, 2025 · Synced Oct 23, 2026, 3:31 PM EDT
Completed Phase 3 Interventional Results available

Starting a Testosterone and Exercise Program After Hip Injury

NCT02938923
View directory record Official record
Conditions
Hip Fracture, Frailty, Sarcopenia
Interventions
Testosterone, Placebo gel, Supervised exercise training, Home exercise program, Health Education Modules
Drug · Behavioral
Lead sponsor
Washington University School of Medicine
Other
Eligibility
65 Years and older · Female only
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
8
States / cities
Aurora, Colorado • Farmington, Connecticut • Baltimore, Maryland + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2025 · Synced Oct 23, 2026, 3:31 PM EDT
Active, not recruiting Phase 1 Interventional Results available

Genetically Engineered HSV-1 Phase 1 Study for the Treatment of Recurrent Malignant Glioma

NCT02062827
View directory record Official record
Conditions
Recurrent Glioblastoma Multiforme, Progressive Glioblastoma Multiforme, Anaplastic Astrocytoma or Gliosarcoma
Interventions
M032 (NSC 733972)
Biological
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2027
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Oct 2, 2025 · Synced Oct 23, 2026, 3:31 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Comparison of High-dose IL-2 and High-dose IL-2 With Radiation Therapy in Patients With Metastatic Melanoma.

NCT01416831
View directory record Official record
Conditions
Metastatic Melanoma
Interventions
Radiation therapy and high-dose IL-2, High-dose IL-2
Other · Drug
Lead sponsor
Providence Health & Services
Other
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2026
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 24, 2026 · Synced Oct 23, 2026, 3:31 PM EDT
Not yet recruiting Phase 2 Interventional

Zanzalintinib in Unresectable and Progressive MPGGs

NCT07714551
View directory record Official record
Conditions
Pheochromocytoma, Paraganglioma
Interventions
Zanzalintinib
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2032
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Oct 23, 2026, 3:31 PM EDT
Completed Phase 2 Interventional Results available

E7389 in Treating Patients With Recurrent or Progressive Stage IIIB or Stage IV Non-Small Cell Lung Cancer

NCT00400829
View directory record Official record
Conditions
Recurrent Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
Interventions
eribulin mesylate
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
2
States / cities
Duarte, California • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 7, 2015 · Synced Oct 23, 2026, 3:31 PM EDT
Completed Phase 1 Interventional

Allogeneic Neuroblastoma Cells for Relapsed/ Refractory Neuroblastoma, CYCHEALL

NCT01713439
View directory record Official record
Conditions
Neuroblastoma
Interventions
Injection of allogeneic neuroblastoma cells
Biological
Lead sponsor
Baylor College of Medicine
Other
Eligibility
Up to 21 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2016
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 12, 2023 · Synced Oct 23, 2026, 3:31 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Internet-Based Pain Coping Skills Training for Patients With Lupus

NCT03933839
View directory record Official record
Conditions
Lupus Erythematosus, Systemic
Interventions
PainCOACH
Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 99 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated May 20, 2020 · Synced Oct 23, 2026, 3:31 PM EDT
Terminated Phase 1 Interventional

Irradiated Donor Lymphocytes and Rituximab in Treating Patients With Relapsed or Refractory Lymphoproliferative Disease

NCT00176475
View directory record Official record
Conditions
Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
Interventions
rituximab, therapeutic allogeneic lymphocytes
Biological
Lead sponsor
University of Medicine and Dentistry of New Jersey
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 17, 2013 · Synced Oct 23, 2026, 3:31 PM EDT
Active, not recruiting Phase 3 Interventional

Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) (REMODEL-2)

NCT05156281
View directory record Official record
Conditions
Relapsing Multiple Sclerosis
Interventions
Remibrutinib, Teriflunomide
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
1,007 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2030
U.S. locations
50
States / cities
Phoenix, Arizona • Hanford, California • Los Angeles, California + 42 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Oct 23, 2026, 3:31 PM EDT
Completed Not applicable Interventional Results available

G-EO Gait Rehabilitation Training in Progressive Multiple Sclerosis

NCT03980145
View directory record Official record
Conditions
Progressive Multiple Sclerosis
Interventions
G-EO System (Reha Technology AG: Olten, Switzerland), Conventional Physical Therapy
Device · Other
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 64 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Feb 14, 2022 · Synced Oct 23, 2026, 3:31 PM EDT
Terminated Phase 2 Interventional Results available

Sacituzumab Govitecan for Relapsed Ovarian, Endometrial, and Cervical Carcinomas

NCT06865677
View directory record Official record
Conditions
Recurrent Platinum Resistant Epithelial Ovarian Carcinoma, Recurrent Epithelial Endometrial Carcinoma, Recurrent Epithelial Cervical Carcinoma
Interventions
Sacituzumab Govitecan, EKG, Brain MRI, CT scans, Tumor biopsy, Loperamide, Octreotide, Diphenoxylate/Atropine, Antiemetics
Drug · Diagnostic Test · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years · Female only
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Oct 23, 2026, 3:31 PM EDT
Completed Not applicable Interventional

Exercise Dose-Response on Features of the Metabolic Syndrome

NCT00687128
View directory record Official record
Conditions
Insulin Resistance, Metabolic Syndrome, Obesity
Interventions
Low-intensity treadmill exercise, Moderate-intensity treadmill exercise, Non-aerobic stretching exercise
Behavioral
Lead sponsor
Charles Drew University of Medicine and Science
Other
Eligibility
18 Years to 60 Years
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 28, 2012 · Synced Oct 23, 2026, 3:31 PM EDT
Completed Phase 2 Interventional Results available

Phase 2 Study of Bevacizumab in Children and Young Adults With NF 2 and Progressive Vestibular Schwannomas

NCT01767792
View directory record Official record
Conditions
Neurofibromatosis Type 2, Progressive Vestibular Schwannomas
Interventions
Bevacizumab
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
6 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
12
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Atlanta, Georgia + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2021 · Synced Oct 23, 2026, 3:31 PM EDT
Not listed Not applicable Interventional

Physical Activity and Quality of Life in Fibrotic Lung Diseases After Initiating Anti-fibrotic Therapy and Pulmonary Rehabilitation

NCT05866198
View directory record Official record
Conditions
Lung Diseases, Interstitial
Interventions
Actigraph CP Insight Watch
Diagnostic Test
Lead sponsor
University of South Florida
Other
Eligibility
40 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Dec 15, 2023 · Synced Oct 23, 2026, 3:31 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Detection and Treatment of Sarcopenia and Myosteatosis in Older African Americans

NCT02350465
View directory record Official record
Conditions
Sarcopenia
Interventions
Eccentric Exercise, Concentric Exercise
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 85 Years
Enrollment
136 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2023
U.S. locations
3
States / cities
Aurora, Colorado • Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jun 2, 2023 · Synced Oct 23, 2026, 3:31 PM EDT
Terminated Phase 1 Interventional

Phase I Dose-Escalation Trial of Clofarabine Followed by Escalating Doses of Fractionated Cyclophosphamide in Children With Relapsed or Refractory Acute Leukemias

NCT00852709
View directory record Official record
Conditions
Myelodysplastic Syndrome, Acute Myeloid Leukemia, Myeloproliferative Disorders, Acute Lymphocytic Leukemia, Acute Promyelocytic Leukemia, Acute Leukemia, Chronic Myelogenous Leukemia, Myelofibrosis, Chronic Myelomonocytic Leukemia, Juvenile Myelomonocytic Leukemia
Interventions
Clofarabine, Cyclophosphamide
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
1 Year to 21 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
6
States / cities
Phoenix, Arizona • Aurora, Colorado • Gainesville, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 15, 2018 · Synced Oct 23, 2026, 3:31 PM EDT
Terminated Phase 3 Interventional Results available

OSE2101 Versus Chemotherapy in HLA-A2 Positive Patients With Advanced NSCLC After Immune Checkpoint Inhibitor Failure

NCT02654587
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
OSE2101, Docetaxel, Pemetrexed
Biological · Drug
Lead sponsor
OSE Immunotherapeutics
Industry
Eligibility
18 Years and older
Enrollment
219 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
10
States / cities
Burbank, California • Washington D.C., District of Columbia • Boca Raton, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2024 · Synced Oct 23, 2026, 3:31 PM EDT
Recruiting Phase 2 Interventional

Evaluation of RBS2418 in Patients With Advanced, Metastatic, and Progressive Colorectal Cancer

NCT06824064
View directory record Official record
Conditions
Metastatic Colorectal Cancer, Advanced Colorectal Cancer
Interventions
RBS2418, Placebo
Drug
Lead sponsor
Riboscience, LLC.
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
Newark, Delaware • Kingwood, Texas
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Oct 23, 2026, 3:31 PM EDT